Technique to enrich CD26high T cells for the treatment of solid malignancies.
- Offers a potent and long-lived T cell product for treating patients with tumors.
- Can translate into industrial production of cellular therapy products for cancer treatment.
Melanoma is the deadliest form of skin cancer, responsible for 80% of skin cancer fatalities. It accounts for less than 2% of skin cancer cases but contributes to the majority of skin cancer deaths. About 106,110 new melanomas will be diagnosed in the US in 2021 and approximately 7,180 people are expected to succumb to this disease. The current method of sorting CD26high T-cells is time-consuming and expensive. A more efficient priming strategy and sorting of CD26high T cells have been developed to enrich CD26high T cells in the context of melanoma. This shows it has applications for the treatment of solid malignancies and can be used to establish foundational aspects of developmental biology for this unique T cell subset as well.
Emory researchers have developed a method to enrich CD26high T cells by priming with exogenous cytokines in vitro. Inventors found that these cells can be enriched and primed with cytotoxic potential using exogenous cytokines in vitro. This is highly unusual for a T cell to make cytokines without mitogenic or TCR stimulation. The team is the first to show that CD26high cells specifically are the ones uniquely responding to this cytokine strategy. Using this method, the yield of CD26high cells were over 10%, whereas the standard method only yields less than 0.5% from peripheral blood mononuclear cells (PBMCs). There is the clinical potential for CD26high T cells as the basis for adoptive cell therapy (ACT) to treat patients with solid malignancies, specifically melanoma.
- Development biology of CD26high T cells.
- Optimize concentration and timing of cytokine stimulation.
- Logistics of cytokine priming alongside traditional stimulation and expansion.
TTO Home Page: https://emoryott.technologypublisher.com
Name: Sat Balachander
Title: Licensing Associate
Phone: (404) 727-4968